Optimizing Access to Care for Patients with Idiopathic Pulmonary Fibrosis
About the Optimizing Access to Care for Patients with Idiopathic Pulmonary Fibrosis Roundtable
3 October 2015
The purpose of this discussion was to bring together multiple stakeholders from across Canada to investigate the current state of evidence and information regarding idiopathic pulmonary fibrosis (IPF) and provide recommendations regarding special considerations for policy making and healthcare decision-making. The draft recommendations will be used to inform a larger stakeholder forum in the new year.
This invitational forum was organized by the Institute of Health Economics (IHE) and was supported by and developed in partnership with Boehringer Ingelheim (Canada) Ltd./Ltée. For this meeting, we invited a small (8-10) group of representative key opinion leaders from the patient, medical, and policy community.
Download Summary Report
Optimizing Access to Care for Patients with Idiopathic Pulmonary Fibrosis - Summary report and draft recommendations
The objectives of this roundtable were to:
- Review the current evidence related to IPF including disease burden, what outcomes and experiences are most valued by patients, and current management strategies;
- Discuss existing frameworks for rare disease and IPF as well as international and national policy initiatives in this area;
- Create draft recommendations to policymakers regarding the minimum set of factors that should be considered when implementing treatment programs for IPF (e.g., use of stopping rules, education, multidisciplinary care) as well as criteria needed for policy decision-making.
The event followed Chatham House rules. Individual comments have been kept confidential but key points raised were discussed in the summary report.
- Optimizing Access to Care for Patients with Idiopathic Pulmonary Fibrosis Multi-stakeholder National Forum (25 April 2016)